EP1253930A4 - Methodes et compositions destinees au traitement du cancer hepatocellulaire - Google Patents

Methodes et compositions destinees au traitement du cancer hepatocellulaire

Info

Publication number
EP1253930A4
EP1253930A4 EP01910587A EP01910587A EP1253930A4 EP 1253930 A4 EP1253930 A4 EP 1253930A4 EP 01910587 A EP01910587 A EP 01910587A EP 01910587 A EP01910587 A EP 01910587A EP 1253930 A4 EP1253930 A4 EP 1253930A4
Authority
EP
European Patent Office
Prior art keywords
compositions
hepatocellular cancer
treating hepatocellular
treating
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01910587A
Other languages
German (de)
English (en)
Other versions
EP1253930A2 (fr
Inventor
James S Economou
Lisa H Butterfield
Bruguera Antoni Ribas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1253930A2 publication Critical patent/EP1253930A2/fr
Publication of EP1253930A4 publication Critical patent/EP1253930A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464481—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP01910587A 2000-02-10 2001-02-12 Methodes et compositions destinees au traitement du cancer hepatocellulaire Ceased EP1253930A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18196600P 2000-02-10 2000-02-10
US181966 2000-02-10
US66025200A 2000-09-12 2000-09-12
US660252 2000-09-12
US66250500A 2000-09-14 2000-09-14
US662505 2000-09-14
PCT/US2001/004539 WO2001058922A2 (fr) 2000-02-10 2001-02-12 Methodes et compositions destinees au traitement du cancer hepatocellulaire

Publications (2)

Publication Number Publication Date
EP1253930A2 EP1253930A2 (fr) 2002-11-06
EP1253930A4 true EP1253930A4 (fr) 2003-05-21

Family

ID=27391498

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01910587A Ceased EP1253930A4 (fr) 2000-02-10 2001-02-12 Methodes et compositions destinees au traitement du cancer hepatocellulaire

Country Status (7)

Country Link
EP (1) EP1253930A4 (fr)
JP (1) JP3876162B2 (fr)
KR (1) KR100482920B1 (fr)
CN (1) CN1255427C (fr)
AU (1) AU2001238179A1 (fr)
HK (1) HK1046853A1 (fr)
WO (1) WO2001058922A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100985914B1 (ko) * 2006-12-13 2010-10-08 주식회사 바이오리더스 간암 특이 항원인 알파­페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물
WO2008113970A2 (fr) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
CN114478791A (zh) * 2015-04-03 2022-05-13 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
CN113321725A (zh) * 2020-02-28 2021-08-31 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
WO1996022787A1 (fr) * 1995-01-24 1996-08-01 Murgita Robert A Alpha-f×toproteine humaine recombinante et ses utilisations
JP3816959B2 (ja) * 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUTTERFIELD L H ET AL: "T cell responses to HLA-A* 0201-restricted peptides derived from human [alpha] fetoprotein", JOURNAL OF IMMUNOLOGY 15 APR 2001 UNITED STATES, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 5300 - 5308, XP002235963, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1253930A2 (fr) 2002-11-06
JP3876162B2 (ja) 2007-01-31
HK1046853A1 (zh) 2003-01-30
JP2003522195A (ja) 2003-07-22
WO2001058922A9 (fr) 2002-10-17
KR20020073203A (ko) 2002-09-19
AU2001238179A1 (en) 2001-08-20
KR100482920B1 (ko) 2005-04-14
CN1398187A (zh) 2003-02-19
WO2001058922A3 (fr) 2002-02-14
CN1255427C (zh) 2006-05-10
WO2001058922A2 (fr) 2001-08-16

Similar Documents

Publication Publication Date Title
AU4768301A (en) Synergistic methods and compositions for treating cancer
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1446114A4 (fr) Compositions et methodes de traitement de l'osteoporose
HUP0201436A3 (en) Methods and compositions for treating solid tumors
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
AU2002219945A1 (en) Composition and method for treating snoring
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
GB0110288D0 (en) Composition and treatment method
EP1468118A4 (fr) Procedes et compositions pour le traitement du cancer
IL144517A0 (en) Compositions and methods for treating cataracts
AU6832101A (en) Composition and method
EP1572118A4 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883
AU4163402A (en) Composition and method
EP1351647A4 (fr) Compositions et methodes pour traiter l'hyperpigmentation
AU2001294686A1 (en) Composition and process for treating metals
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
PL368948A1 (en) Process and composition for treating wood
EP1282411A4 (fr) Methode de traitement anticancereux
HK1046853A1 (zh) 治療肝癌的方法及組成物
GB0123898D0 (en) Method for treating objects
GB0118883D0 (en) Method for treating objects
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
EP1261331A4 (fr) Procede et compositions permettant de traiter les maladies fibrosantes
GB0122810D0 (en) Method for treating objects

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020724

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20061230

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046853

Country of ref document: HK